Lifelong TMAO exposure exerts hypotensive effects in aged spontaneously hypertensive rats
In male SHR rats, lifelong TMAO supplementation over 80 weeks reduced blood pressure during aging — a favorable direction in this animal model that cannot be extrapolated to humans.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Blood pressure | D | ▲ Favorable | Direction: decreased in TMAO group vs control in aged SHR; exact MD and 95% CI not available in supplied text | 1 |
| Survival | D | — Insufficient | Quantitative survival data (HR or absolute numbers) not reported in supplied text excerpt | 1 |
| Tissue RAS component expression | D | ▲ Favorable | Directional changes reported in multiple tissues; specific fold-change, 95% CI not available in supplied text | 1 |
| Structural cardiovascular parameters (cardiac hypertrophy, fibrosis) | D | — Insufficient | Quantitative structural data not reported in supplied text excerpt | 1 |
Context
TMAO is consistently linked to cardiovascular risk in human observational studies, but experimental evidence yields contradictory results. Most studies use young animal models, ignoring the chronic impact of this metabolite. This study addresses the gap in longitudinal assessment in aged hypertensive animals.
What the study showed
Lifelong TMAO exposure was associated with reduced blood pressure in aged SHR rats compared to controls. Alterations in tissue RAS component expression were observed across multiple organs. The available text does not report absolute values, 95% CIs, or precise numerical effect sizes for all outcomes, limiting quantification. The hypotensive effect was detected in the aging phase, not in early supplementation stages.
How it was done
Controlled animal experiment (non-RCT) in male SHR rats supplemented with TMAO for 80 weeks until aging. Animals were monitored for circulatory parameters, survival, and gene/protein expression of RAS components in multiple tissues. The text provided corresponds mainly to the introduction and methods; complete quantitative results data were not fully available in the supplied excerpt.
Effect magnitude
Precise numerical data (95% CI, effect size) were not reported in the available text excerpt; the magnitude of the hypotensive effect cannot be rigorously quantified from the supplied material.
Limitations
Exclusively animal model (male SHR rats) with no direct applicability to humans — no formal animal study risk of bias tool applied (e.g., SYRCLE). Small sample size typical of preclinical studies, with no formal randomization described. Absence of a normotensive control group (e.g., Wistar-Kyoto). The full results and discussion text was not completely provided, preventing full critical appraisal of quantitative data and statistical analyses.
In clinical practice
This study does not support any clinical recommendation for TMAO supplementation or reduction in hypertensive patients. Clinicians should maintain the interpretation of TMAO as an associative, not causal, cardiovascular risk biomarker in humans. Controlled clinical trials are needed before any change in clinical practice.
What is still missing
Human studies (RCTs or prospective cohorts) evaluating the effect of interventions targeting circulating TMAO in aged hypertensive individuals. Replication in female animal models and in non-genetic hypertension models.